Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

IRVINE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus will participate in a fireside chat at the Virtual Jefferies London Healthcare Conference. Fireside Chat Presentation Details The fireside chat will be available on-demand beginning Thursday, November 18th at 8:00am GT / 12:00am PT through Friday, November 19th Management will also host virtual one-on-one meetings on November 19, 2021. For additional information or to schedule a meeting, please contact your Jefferies representative. The above listed dates are subject to change. Details on the presentation time or changes to the presentation date can be found on the Company’s website. Please check www.tarsusrx.com for the latest information. A live webcast of the presentation will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial. Contacts: Media Contact:SuJin Oh Shop PR(917) [email protected] Investor Contact:David NakasoneHead of Investor Relations(949) [email protected]